Nature’S Sun SEC Filings

Nature's Sunshine Products, Inc. (NATR) – Form 144 filing discloses that insider Richard D. Moss Revocable Trust intends to sell 1,000 common shares through broker Wells Fargo Clearing Services on or about 07 July 2025. Based on the reference price in the notice, the proposed transaction is valued at $15,931.15. The filing shows 18,350,801 shares outstanding; the planned sale therefore represents roughly 0.005 % of outstanding shares.

More importantly, the trust and Richard D. Moss have been active sellers during the past three months. The table included in the filing lists 18 separate transactions between 9 May 2025 and 7 July 2025, totaling 46,234 shares and generating gross proceeds of approximately $675,514. This cumulative amount equals about 0.25 % of the company’s shares outstanding. While neither the filing nor Rule 144 requires disclosure of motives, sustained insider selling can be interpreted by some investors as a signal of reduced near-term confidence or personal diversification.

The shares to be sold were originally acquired via restricted share grants and compensation on 6 May 2024; no cash outlay or special consideration was involved. The signatory certifies that no material non-public adverse information is known at the time of filing.

Takeaways for investors:

• The upcoming 1,000-share sale is immaterial in isolation, but it comes after a pattern of sizable disposals by the same beneficial owner.
• Total insider sales of >46 k shares in three months, although small relative to float, may draw attention to management’s sentiment and potential supply overhang.
• No operational or financial performance data are included; the filing is solely a notice of proposed sales under Rule 144.

Nature’s Sunshine Products Inc. (NATR) – Form 4 insider transaction filed 27 June 2025

The filing discloses that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma") and its wholly-owned subsidiary Fosun Pharma USA Inc.—both classified as 10 % owners—sold 2,854,607 shares of NATR common stock on 27 June 2025. The disposition, coded “S”, was executed at a reported price of $11.46 per share pursuant to an Underwriting Agreement dated 25 June 2025.

• Post-transaction holdings: Fosun Pharma USA Inc. now reports 0 shares; Fosun Pharma’s remaining indirect ownership is 64,167 shares held through another wholly-owned subsidiary, Fosun Industrial Co., Limited.
• Percentage change: The sale represents > 97 % reduction in Fosun’s reported stake, effectively eliminating its direct position.
• No derivative securities were reported.

The filing signals a material reduction of a long-standing 10 % shareholder’s position, increasing NATR’s public float and potentially altering future governance dynamics. No earnings or operational data are included in this Form 4.

Nature's Sunshine Products (Nasdaq:NATR) filed an 8-K announcing a secondary public offering of 2,854,607 shares by major holder Fosun Pharma USA at $12.00 per share (≈$34.3 million to the seller). The company will not receive proceeds but may repurchase up to $15 million of these shares under its existing authorization, with any bought stock cancelled. Closing is slated for 27 June 2025; a 90-day lock-up applies to insiders and the selling stockholder. The underwriting agreement with D.A. Davidson & Co. carries standard terms and indemnities, and any buyback would be funded with cash and the credit facility.